FDA Approved of AI-Powered Software: The Future of Radiology

New AI tool gives radiology a boost—detecting cancer doctors might miss.

FDA Approved of AI-Powered Software: The Future of Radiology

In recent technological advancements, the U.S. Food and Drug Administration (FDA) has approved a groundbreaking software that is set to revolutionize the world of radiology. This software, developed by Imidex Inc., not only showcases the potential of artificial intelligence in medical imaging but also underlines the pivotal role technology plays in shaping the future of healthcare.

The Dawn of AI in Radiology

It's no longer the stuff of science fiction. On August 18, 2023, Imidex Inc. declared that their artificial intelligence-powered software, VisiRad XR, had received clearance from the FDA. This software's primary function? Identifying suspicious findings on chest X-rays, a task that is of immense importance in the early detection of conditions such as lung cancer.

The Making of VisiRad XR

The birth of VisiRad XR is a testament to global collaboration. Its development involved curated datasets from all over the world, ensuring a comprehensive and diverse range of data. By employing state-of-the-art machine learning techniques, this software analyzes radiographs to highlight potential nodules and masses that might have gone unnoticed.

Dr. Raj Chopra, MD, a radiologist and chief medical officer, emphasized the significance of such technological advancements. He stated, "Radiologists are looking for solutions to help elevate their performance and reduce burnout." With the increasing volume of patients and decreasing staff, tools like VisiRad XR are not just a boon for patient care, but they also empower radiologists to harness their full potential.

Integration into the Current System

One of the remarkable attributes of VisiRad XR is its adaptability. Imidex assures that the Denver-based software can seamlessly integrate into existing imaging workflows. This means that as radiologists go about their routine, the results from VisiRad XR can be viewed almost instantaneously, positioned conveniently right behind the primary image for interpretation.

The Evidence: VisiRad XR in Action

Before the FDA gave its nod, Imidex subjected VisiRad XR to rigorous testing. Two large-scale studies were conducted to assess its efficiency. The numbers speak for themselves: in a standalone analysis of over 11,000 images, VisiRad XR detected nodules and masses with an impressive sensitivity of 83%. Moreover, given its performance, Imidex estimates that at an average hospital, which conducts about 50,000 chest X-rays annually, VisiRad XR could identify an additional 750 lung nodules or masses in just one year.

Concluding Thoughts: The Intersection of Humanity and Technology

In the vast landscape of medical technology, VisiRad XR stands as a beacon, reminding us of the human aspect behind every technological advancement. By reducing the chances of oversight and aiding radiologists in their endeavours, this software not only enhances the quality of medical care but also safeguards the well-being of the medical professionals dedicated to our care.

In the words of Dr Chopra, tools like VisiRad XR are "beneficial not only for patient care but for helping radiologists continue to practice to their full potential." It's not just about machines or algorithms; it's about people, their health, and the professionals committed to ensuring it.

Original Article


Read next